We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alexandria (ARE) to Post Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Alexandria Real Estate Equities (ARE - Free Report) is scheduled to report fourth-quarter results on Feb 4, after the market closes. The company’s results will likely reflect year-over-year growth in its funds from operations (FFO) per share and revenues.
In the last reported quarter, this Pasadena, CA-based urban office real estate investment trust (REIT), which primarily focuses on collaborative life-science and technology campuses, posted adjusted FFO of $1.66 per share, missing the Zacks Consensus Estimate by a penny. Results reflected decent internal and external growth. The company witnessed increase in rental rate and net operating income (NOI).
Over the trailing four quarters, the company surpassed the Zacks Consensus Estimate in one occasion, missed in another two and met in the other. It delivered average positive surprise of 0.16% during this period. The graph below depicts this surprise history:
Alexandria Real Estate Equities, Inc. Price and EPS Surprise
For 2018, Alexandria anticipates adjusted FFO per share of $6.59-$6.61. The Zacks Consensus Estimate for the same is pegged at $6.62, representing year-over-year growth of approximately 10%.
Let’s see how things are shaping up prior to this announcement.
Factors to Consider
In the Oct-Dec quarter, Alexandria made strategic efforts to enhance its life-science and technology campus portfolio in a bid to gain from the strengthening industry fundamentals.
In October, the company started development of the North Tower at the Alexandria Centerfor Life Science – New York City, thereby, banking on the city’s emerging life-science cluster space.Further, the company expanded its ownership in New York City to more than two million rentable square feet (RSF) of space, including a development/redevelopment pipeline of 1.3 million RSF.
In addition, in December, it announced the expansion of the company’s full-service life-science start-up platform, Alexandria LaunchLabs, opening at the Alexandria Center in One Kendall Square. The platform intends to provide a solid start-up platform for life-science companies. This, in turn, will spur demand for life-science space.
Hence, we anticipate the company to have witnessed solid demand from life-science and tech tenants during the fourth quarter, on the back of these efforts. Moreover, we expect the company to have witnessed healthy rent escalations and leasing activity at positive rent spreads, given the strategic location of its clusters. This will likely have boosted Alexandria’s fourth-quarter revenues. In fact, the Zacks Consensus Estimate for the same is pegged at $344.5 million and reflects a year-over-year jump of 15.3%.
Although the company initiated development projects in a bid to strengthen its life-science portfolio, amid rising construction-cost scenario, we anticipate Alexandria to have witnessed cost overruns. This will likely decrease development returns for its development projects and in turn, adversely impact its fourth-quarter bottom-line performance.
Lastly, the rising interest-rate environment remains a challenge, since the company has exposure to long-term leased assets. Furthermore, it is expected to have escalated cost of financing the company’s development pipeline.
Hence, there is lack of any solid catalyst prior to the fourth-quarter earnings release. As such, the Zacks Consensus Estimate for FFO per share for the to-be-reported quarter remained unchanged at $1.69 over the past month. Nonetheless, it represents year-over-year growth of 10.5%.
Earnings Whispers
Our proven model does not conclusively show that Alexandria is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or at least 3 (Hold) for this to happen. That is not the case here, as you will see below.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Alexandria’s Earnings ESP is 0.00%.
Zacks Rank: The company currently carries a Zacks Rank of 2, which increases the predictive power of ESP. However, we also need a positive ESP to be confident of the earnings beat.
Stocks That Warrant a Look
While the other players in this space are lined up to report their financial results, below are three stocks, poised to beat on earnings per the proven Zacks model. You can see the complete list of today’s Zacks #1 Rank stocks here.
AvalonBay Communities (AVB - Free Report) , slated to report fourth-quarter results on Feb 4, has an Earnings ESP of +0.22% and holds a Zacks Rank of 3.
American Tower Corporation (AMT - Free Report) , set to release earnings on Feb 27, has an Earnings ESP of +0.29% and carries a Zacks Rank of 3.
Omega Healthcare Investors, Inc. (OHI - Free Report) , scheduled to report quarterly numbers on Feb 11, has an Earnings ESP of +0.26% and carries a Zacks Rank of 2.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Alexandria (ARE) to Post Q4 Earnings: What's in the Cards?
Alexandria Real Estate Equities (ARE - Free Report) is scheduled to report fourth-quarter results on Feb 4, after the market closes. The company’s results will likely reflect year-over-year growth in its funds from operations (FFO) per share and revenues.
In the last reported quarter, this Pasadena, CA-based urban office real estate investment trust (REIT), which primarily focuses on collaborative life-science and technology campuses, posted adjusted FFO of $1.66 per share, missing the Zacks Consensus Estimate by a penny. Results reflected decent internal and external growth. The company witnessed increase in rental rate and net operating income (NOI).
Over the trailing four quarters, the company surpassed the Zacks Consensus Estimate in one occasion, missed in another two and met in the other. It delivered average positive surprise of 0.16% during this period. The graph below depicts this surprise history:
Alexandria Real Estate Equities, Inc. Price and EPS Surprise
Alexandria Real Estate Equities, Inc. Price and EPS Surprise | Alexandria Real Estate Equities, Inc. Quote
For 2018, Alexandria anticipates adjusted FFO per share of $6.59-$6.61. The Zacks Consensus Estimate for the same is pegged at $6.62, representing year-over-year growth of approximately 10%.
Let’s see how things are shaping up prior to this announcement.
Factors to Consider
In the Oct-Dec quarter, Alexandria made strategic efforts to enhance its life-science and technology campus portfolio in a bid to gain from the strengthening industry fundamentals.
In October, the company started development of the North Tower at the Alexandria Centerfor Life Science – New York City, thereby, banking on the city’s emerging life-science cluster space.Further, the company expanded its ownership in New York City to more than two million rentable square feet (RSF) of space, including a development/redevelopment pipeline of 1.3 million RSF.
In addition, in December, it announced the expansion of the company’s full-service life-science start-up platform, Alexandria LaunchLabs, opening at the Alexandria Center in One Kendall Square. The platform intends to provide a solid start-up platform for life-science companies. This, in turn, will spur demand for life-science space.
Hence, we anticipate the company to have witnessed solid demand from life-science and tech tenants during the fourth quarter, on the back of these efforts. Moreover, we expect the company to have witnessed healthy rent escalations and leasing activity at positive rent spreads, given the strategic location of its clusters. This will likely have boosted Alexandria’s fourth-quarter revenues. In fact, the Zacks Consensus Estimate for the same is pegged at $344.5 million and reflects a year-over-year jump of 15.3%.
Although the company initiated development projects in a bid to strengthen its life-science portfolio, amid rising construction-cost scenario, we anticipate Alexandria to have witnessed cost overruns. This will likely decrease development returns for its development projects and in turn, adversely impact its fourth-quarter bottom-line performance.
Lastly, the rising interest-rate environment remains a challenge, since the company has exposure to long-term leased assets. Furthermore, it is expected to have escalated cost of financing the company’s development pipeline.
Hence, there is lack of any solid catalyst prior to the fourth-quarter earnings release. As such, the Zacks Consensus Estimate for FFO per share for the to-be-reported quarter remained unchanged at $1.69 over the past month. Nonetheless, it represents year-over-year growth of 10.5%.
Earnings Whispers
Our proven model does not conclusively show that Alexandria is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or at least 3 (Hold) for this to happen. That is not the case here, as you will see below.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Alexandria’s Earnings ESP is 0.00%.
Zacks Rank: The company currently carries a Zacks Rank of 2, which increases the predictive power of ESP. However, we also need a positive ESP to be confident of the earnings beat.
Stocks That Warrant a Look
While the other players in this space are lined up to report their financial results, below are three stocks, poised to beat on earnings per the proven Zacks model. You can see the complete list of today’s Zacks #1 Rank stocks here.
AvalonBay Communities (AVB - Free Report) , slated to report fourth-quarter results on Feb 4, has an Earnings ESP of +0.22% and holds a Zacks Rank of 3.
American Tower Corporation (AMT - Free Report) , set to release earnings on Feb 27, has an Earnings ESP of +0.29% and carries a Zacks Rank of 3.
Omega Healthcare Investors, Inc. (OHI - Free Report) , scheduled to report quarterly numbers on Feb 11, has an Earnings ESP of +0.26% and carries a Zacks Rank of 2.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>